Scribe Therapeutics, Inc. (SCTX) stock
SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.05−1.72 (-10.91%)
Close on Nov 18, 2026Market cap $34.92MP/E –Yield –
Scribe Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.92M | – |
| Q2 FY2025 | Jun 30, 2025 | $4.90M | – |
See a number that looks wrong?